Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q3 2023 · 10-Q
Revenue$16.33M$16.33M+8.3% vs Q3 2022 Net Income-$2.87M-$2.87MN/M vs Q3 2022 EPS Diluted-$0.17-$0.17N/M vs Q3 2022 Gross Profit$9,800,000+4.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flowderived$1,473,000−57.5% Free Cash Flowderived$1,439,556−58.1% Margins · derivedGross margin60.0%−2.4 pt vs Q3 2022
Operating margin-21.8%+3.1 pt vs Q3 2022
Net margin-17.5%+5.4 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 14, 2023 · 45 d after period end